Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
156 results about "FGF21" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Fibroblast growth factor 21 is a protein that in mammals is encoded by the FGF21 gene. The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family and specifically a member of the endocrine subfamily which includes FGF23 and FGF15/19. FGF21 is the primary endogenous agonist of the FGF21 receptor, which is composed of the co-receptors FGF receptor 1 and β-Klotho.
Method for activating receptor by cofactor and method for utilizing ligand activity
InactiveUS20100184665A1Increase and inhibits activityExcellent screening systemCompound screeningOrganic active ingredientsCell systemBULK ACTIVE INGREDIENT
Using betaKlotho or a substance that increases or inhibits betaKlotho activity as an agent for controlling the activity of FGF21 mediated by an FGF receptor, the present invention provides a pharmaceutical composition comprising such betaKlotho or such substance as an active ingredient, particularly, a pharmaceutical composition for anti-metabolic syndrome, and further particularly, a pharmaceutical composition for therapeutic or preventive use associated with the control of blood glucose level. In addition, the present invention provides a screening system for each of a substance that enhances or suppresses betaKlotho activity, an FGF21-like active substance, and a betaKlotho-like active substance, which uses a cell system that has expressed an FGF receptor and / or betaKlotho on the surface thereof.
Owner:NAT INST OF ADVANCED IND SCI & TECH
Compositions, uses and methods for treatment of metabolic disorders and diseases
ActiveUS20130023474A1Lower Level RequirementsIncrease insulin sensitivityOrganic active ingredientsFungiDiseaseFGF19
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Owner:NGM BIOPHARMLS
Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity, and related metabolic disorders
The present invention relates to chimeric proteins that include an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion of fibroblast growth factor 21 (“FGF21”) and the C-terminus includes a C-terminal portion of fibroblast growth factor 19 (“FGF19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased FGF21-βKlotho-FGF receptor complex formation, methods of causing increased FGF21 receptor agonist-βKlotho-FGF receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention.
Owner:NEW YORK UNIV
Fibroblast growth factor-21-Fc fusion proteins
ActiveUS9006400B2Easy to controlImproved profilePeptide/protein ingredientsAntibody mimetics/scaffoldsProtein CFibroblast growth factor receptor 1
The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
Owner:NOVARTIS AG
Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
ActiveUS8951966B2Lower Level RequirementsIncrease insulin sensitivityOrganic active ingredientsBacteriaDiseaseFGF19
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Owner:NGM BIOPHARMLS
Compositions and methods for treatment of metabolic disorders and diseases
InactiveUS20150291677A1Effective treatmentPromote sugar metabolismBacteriaPeptide/protein ingredientsDiseaseFGF19
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Owner:NGM BIOPHARMLS
Methods of treating fgf21-associated disorders
InactiveUS20120129766A1Good biological propertiesPeptide/protein ingredientsAntibody mimetics/scaffoldsFibroblast growth factorFGF21
The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
Owner:NOVARTIS AG
Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject
ActiveUS9089525B1Lower Level RequirementsIncrease insulin sensitivityPeptide/protein ingredientsMetabolism disorderDiseaseAcute hyperglycaemia
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Owner:NGM BIOPHARMLS
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
Owner:NGM BIOPHARMLS
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
Owner:NGM BIOPHARMLS
Compositions comprising variants and fusions of FGF19 polypeptides
ActiveUS9290557B2Reduced glucose levelIncrease insulin sensitivityBacteriaPeptide/protein ingredientsAcute hyperglycaemiaFGF19
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Owner:NGM BIOPHARMLS
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
ActiveUS20170182123A1Improves bile acid homeostasisReduce doseAntibody mimetics/scaffoldsSulfonylurea active ingredientsDiseaseFGF19
Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.
Owner:NGM BIOPHARMLS
Compositions, uses and methods for treatment of metabolic disorders and diseases
InactiveUS20160200788A1Lower Level RequirementsIncrease insulin sensitivityPeptide/protein ingredientsMetabolism disorderDiseaseFGF19
Owner:NGM BIOPHARMLS
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
Owner:NGM BIOPHARMLS
Dual function proteins for treating metabolic disorders
ActiveUS20130129724A1Easy to controlImproved profilePeptide/protein ingredientsAntibody mimetics/scaffoldsFibre cellMetabolic profile
The present invention relates to the identification of new proteins comprising fibroblast growth factor 21 (FGF21) and other metabolic regulators, including variants thereof, known to improve metabolic profiles in subjects to whom they are administered. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.
Owner:NOVARTIS AG
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
Owner:NGM BIOPHARMLS
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
Owner:NGM BIOPHARMLS
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
Owner:NGM BIOPHARMLS
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
Owner:NGM BIOPHARMLS
Methods and compositions for the treatment of metabolic disorders and diseases
ActiveUS20170182122A1Lower Level RequirementsIncrease insulin sensitivityPeptide/protein ingredientsBiological material analysisDiseaseFGF19
Provided herein are variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Owner:NGM BIOPHARMLS
Fibroblast growth factor 21 mutations
InactiveUS9023791B2Good biological propertiesPeptide/protein ingredientsAntibody mimetics/scaffoldsBiologyFGF21
The present invention provides novel polypeptide and protein variants of fibroblast growth factor 21 (FGF21) and pharmaceutical compositions comprising FGF21 polypeptide and protein variants.
Owner:NOVARTIS AG
Preparation and application of human fibroblast growth factor 21 fusion protein and mutant of human fibroblast growth factor 21 fusion protein
InactiveCN102558358AGood effectStrong penetrating powerPeptide/protein ingredientsMetabolism disorderHalf-lifeHinge region
The invention provides a fusion protein used for detecting and treating human I-type diabetes mellitus and human II-type diabetes mellitus and obesity as well as a preparation and an application of the fusion protein. The fusion protein contains a human FGF21 or a mutant thereof and a human IgG2-Fc (hinge region -CH2-CH3) or a human IgG2-Fc mutant ( T250Q / M428L and T307Q / N434A), can improve the living condition of the obesity patients, reduce the blood sugar level of diabetics, effectively reduce aggregation and degradation of the FGF21 protein, and meanwhile prolong in vivo half-life period of the FGF21, and especially through the fusion of the FGF21 and the mutant and the IgG-Fc (T250Q / M428L and T307Q / N434A) mutant, the affinity with FcRn is enhanced, and in vivo half-life period of the FGF21 is further prolonged.
Owner:北京康明百奥科技有限公司
Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having bile acid diarrhea or bile acid malabsorption
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
Owner:NGM BIOPHARMLS
GLP-1 and FGF21 combinations for treatment of diabetes type 2
The invention relates to the use of a Fibroblast Growth Factor 21 (FGF21 ) compound and a Glucagon-Like Peptide 1 (GLP-1 ) compound in combination for the preparation of a medicament for the treatment of diabetes, more in particular type 2 diabetes, as well as pharmaceutical compositions comprising certain FGF21 and GLP-1 compounds in combination, together with a pharmaceutically acceptable carrier. The combination has a significant effect on parameters of relevance for diabetes type 2, viz. on the viability of [beta] cells ex vivo in the presence of free fatty acids, on caspase activity of [beta] cells ex vivo (a measure of cell apoptosis), and a blood glucose lowering effect on db / db mice in vivo.
Owner:NOVO NORDISK AS
Method for producing secretion expression recombinant human fibroblast growth factor-21
ActiveCN101376888ASimple purification processImprove yieldBacteriaMicroorganism based processesSecretion expressionNucleotide sequencing
The invention provides a method for producing FGF21. The invention first designs and synthetizes full-length FGF21 nucleotide sequence which is integrated with secreted signal peptide to be structured into an expression carrier capable of secreting and expressing FGF21 protein; the expression carrier is led into an appropriate host cell; under the guidance of the secreted signal peptide, FGF21 is expressed in cell periplasm, so that the purification procedure is convenient, the finished product ratio is improved and the mass production of rhFGF-21 becomes possible.
Owner:李校堃 +2
Methods of treating, diagnosing or detecting fgf21-associated disorders
The invention provides, inter alia, methods for treating cancer and vascular disease, compositions for treating cancer and vascular disease, and methods and compositions for diagnosing and / or detecting cancer and vascular disease.
Owner:NOVARTIS AG
Synergistic bifunctional protein for regulating blood sugar and lipid
The invention relates to a synergistic bifunctional protein for regulating blood sugar and lipid. The synergistic bifunctional protein comprises a human GLP-1 analog and human FGF21. In one aspect, the invention provides a method for preparing the synergistic bifunctional protein, and on the other hand, the invention also provides an application of the synergistic bifunctional protein for treatment of type 2 diabetes, obesity, dyslipidemia, fatty liver disease and / or metabolism syndrome drugs. The synergistic bifunctional protein provided by the invention can synergistically regulate blood sugar and lipid levels in vivo, and meet the multiple needs of hypoglycemia, alleviation of liver fatty degeneration, weight reduction and improvement of circulating lipid metabolism disorder in type 2 diabetic patients.
Owner:AMPSOURCE BIOPHARMA (SHANGHAI) INC
Double-target fusion protein containing immune globulin Fc portion
ActiveCN108570109AImprove stabilityCausing random combinationsPeptide/protein ingredientsMetabolism disorderBiochemistryLipid lowering
Owner:SUNSHINE LAKE PHARM CO LTD
Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject
InactiveUS9963494B2Lower Level RequirementsIncrease insulin sensitivityPeptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseAcute hyperglycaemia
Owner:NGM BIOPHARMLS
Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to fgf21
ActiveUS20130035373A1Modulate its functionOrganic active ingredientsGenetic material ingredientsDiseasePolynucleotide
The present invention relates to antisense oligonucleotides that modulate the expression of and / or function of Fibroblast growth factor 21 (FGF21), in particular, by targeting natural antisense polynucleotides of Fibroblast growth factor 21 (FGF21). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of FGF21.
Owner:CURNA INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com